158 related articles for article (PubMed ID: 24942502)
1. Long-term persistence and switching patterns among women using osteoporosis therapies: 24- and 36-month results from POSSIBLE US™.
Wade SW; Satram-Hoang S; Stolshek BS
Osteoporos Int; 2014 Sep; 25(9):2279-90. PubMed ID: 24942502
[TBL] [Abstract][Full Text] [Related]
2. Treatment satisfaction and persistence among postmenopausal women on osteoporosis medications: 12-month results from POSSIBLE US™.
Barrett-Connor E; Wade SW; Do TP; Satram-Hoang S; Stewart R; Gao G; Macarios D
Osteoporos Int; 2012 Feb; 23(2):733-41. PubMed ID: 21625886
[TBL] [Abstract][Full Text] [Related]
3. Persistence and switching patterns among women with varied osteoporosis medication histories: 12-month results from POSSIBLE US.
Tosteson AN; Do TP; Wade SW; Anthony MS; Downs RW
Osteoporos Int; 2010 Oct; 21(10):1769-80. PubMed ID: 20101492
[TBL] [Abstract][Full Text] [Related]
4. Self-reported calcium use in a cohort of postmenopausal women receiving osteoporosis therapy: results from POSSIBLE US™.
Barrett-Connor E; Wade SW; Downs RW; Ganiats T; Hochberg M; Recker RR; Stolshek BS
Osteoporos Int; 2015 Aug; 26(8):2175-84. PubMed ID: 25876880
[TBL] [Abstract][Full Text] [Related]
5. Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study.
Hadji P; Papaioannou N; Gielen E; Feudjo Tepie M; Zhang E; Frieling I; Geusens P; Makras P; Resch H; Möller G; Kalouche-Khalil L; Fahrleitner-Pammer A
Osteoporos Int; 2015 Oct; 26(10):2479-89. PubMed ID: 26018090
[TBL] [Abstract][Full Text] [Related]
6. The impact of GI events on persistence and adherence to osteoporosis treatment: 3-, 6-, and 12-month findings in the MUSIC-OS study.
Modi A; Sen S; Adachi JD; Adami S; Cortet B; Cooper AL; Geusens P; Mellström D; Weaver JP; van den Bergh JP; Keown P; Sajjan S
Osteoporos Int; 2018 Feb; 29(2):329-337. PubMed ID: 29110061
[TBL] [Abstract][Full Text] [Related]
7. Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study.
Silverman SL; Siris E; Kendler DL; Belazi D; Brown JP; Gold DT; Lewiecki EM; Papaioannou A; Simonelli C; Ferreira I; Balasubramanian A; Dakin P; Ho P; Siddhanti S; Stolshek B; Recknor C
Osteoporos Int; 2015 Jan; 26(1):361-72. PubMed ID: 25236877
[TBL] [Abstract][Full Text] [Related]
8. Design of the POSSIBLE UStrade mark Study: postmenopausal women's compliance and persistence with osteoporosis medications.
Barrett-Connor E; Ensrud K; Tosteson AN; Varon SF; Anthony M; Daizadeh N; Wade S
Osteoporos Int; 2009 Mar; 20(3):463-72. PubMed ID: 18607669
[TBL] [Abstract][Full Text] [Related]
9. Impact of medication adherence on health care utilization and productivity: self-reported data from a cohort of postmenopausal women on osteoporosis therapy.
Wade SW; Satram-Hoang S; Nadkar A; Macarios D; Tosteson AN
Clin Ther; 2011 Dec; 33(12):2006-15. PubMed ID: 22099387
[TBL] [Abstract][Full Text] [Related]
10. The non-interventional BonViva Intravenous Versus Alendronate (VIVA) study: real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis.
Hadji P; Felsenberg D; Amling M; Hofbauer LC; Kandenwein JA; Kurth A
Osteoporos Int; 2014 Jan; 25(1):339-47. PubMed ID: 24091594
[TBL] [Abstract][Full Text] [Related]
11. Low persistence with oral biphosphonate treatment in postmenopausal osteoporosis.
Torre C; Guerreiro J; Mendes Z; Miranda A; Bragança F; Cristino J; Canhão H; Branco JC
Acta Reumatol Port; 2019; 44(2):114-125. PubMed ID: 31280276
[TBL] [Abstract][Full Text] [Related]
12. Adherence and profile of non-persistence in patients treated for osteoporosis--a large-scale, long-term retrospective study in The Netherlands.
Netelenbos JC; Geusens PP; Ypma G; Buijs SJ
Osteoporos Int; 2011 May; 22(5):1537-46. PubMed ID: 20838773
[TBL] [Abstract][Full Text] [Related]
13. One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study.
Reyes C; Tebe C; Martinez-Laguna D; Ali MS; Soria-Castro A; Carbonell C; Prieto-Alhambra D
Osteoporos Int; 2017 Oct; 28(10):2997-3004. PubMed ID: 28714038
[TBL] [Abstract][Full Text] [Related]
14. Natural history, reasons for, and impact of low/non-adherence to medications for osteoporosis in a cohort of community-dwelling older women already established on medication: a 2-year follow-up study.
Clark EM; Gould VC; Tobias JH; Horne R
Osteoporos Int; 2016 Feb; 27(2):579-90. PubMed ID: 26286625
[TBL] [Abstract][Full Text] [Related]
15. Physician differences in managing postmenopausal osteoporosis: results from the POSSIBLE US™ treatment registry study.
Lukert B; Satram-Hoang S; Wade S; Anthony M; Gao G; Downs R
Drugs Aging; 2011 Sep; 28(9):713-27. PubMed ID: 21913737
[TBL] [Abstract][Full Text] [Related]
16. Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States.
Durden E; Pinto L; Lopez-Gonzalez L; Juneau P; Barron R
Arch Osteoporos; 2017 Dec; 12(1):22. PubMed ID: 28243883
[TBL] [Abstract][Full Text] [Related]
17. Factors associated with high 24-month persistence with denosumab: results of a real-world, non-interventional study of women with postmenopausal osteoporosis in Germany, Austria, Greece, and Belgium.
Fahrleitner-Pammer A; Papaioannou N; Gielen E; Feudjo Tepie M; Toffis C; Frieling I; Geusens P; Makras P; Boschitsch E; Callens J; Anastasilakis AD; Niedhart C; Resch H; Kalouche-Khalil L; Hadji P
Arch Osteoporos; 2017 Dec; 12(1):58. PubMed ID: 28643265
[TBL] [Abstract][Full Text] [Related]
18. Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis.
Karlsson L; Lundkvist J; Psachoulia E; Intorcia M; Ström O
Osteoporos Int; 2015 Oct; 26(10):2401-11. PubMed ID: 26282229
[TBL] [Abstract][Full Text] [Related]
19. Increased treatment persistence and its determinants in women with osteoporosis with prior fracture compared to those without fracture.
Jacob L; Dreher M; Kostev K; Hadji P
Osteoporos Int; 2016 Mar; 27(3):963-969. PubMed ID: 26519418
[TBL] [Abstract][Full Text] [Related]
20. Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study.
Silverman SL; Siris E; Belazi D; Recknor C; Papaioannou A; Brown JP; Gold DT; Lewiecki EM; Quinn G; Balasubramanian A; Yue S; Stolshek B; Kendler DL
Arch Osteoporos; 2018 Aug; 13(1):85. PubMed ID: 30088189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
